B

Bonus Biogroup Ltd
TASE:BONS

Watchlist Manager
Bonus Biogroup Ltd
TASE:BONS
Watchlist
Price: 9.9 ILS 1.02% Market Closed
Market Cap: 121.1m ILS
Have any thoughts about
Bonus Biogroup Ltd?
Write Note

Bonus Biogroup Ltd
Accrued Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Bonus Biogroup Ltd
Accrued Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accrued Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
B
Bonus Biogroup Ltd
TASE:BONS
Accrued Liabilities
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Collplant Biotechnologies Ltd
NASDAQ:CLGN
Accrued Liabilities
$2.3m
CAGR 3-Years
73%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Kamada Ltd
NASDAQ:KMDA
Accrued Liabilities
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Enlivex Therapeutics Ltd
NASDAQ:ENLV
Accrued Liabilities
$2.5m
CAGR 3-Years
-8%
CAGR 5-Years
13%
CAGR 10-Years
N/A
Urogen Pharma Ltd
NASDAQ:URGN
Accrued Liabilities
$24m
CAGR 3-Years
18%
CAGR 5-Years
16%
CAGR 10-Years
N/A
Entera Bio Ltd
NASDAQ:ENTX
Accrued Liabilities
$927k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Bonus Biogroup Ltd
Glance View

Market Cap
121.1m ILS
Industry
Biotechnology

Bonus Biogroup Ltd. is a biotechnology company engaging in the field of stem cells and tissue engineering. The firm is developing cell therapy products based on autologous and allogeneic bone implants that will enable efficient bone transplant and provide cellular-based bone replacement prosthetics for repairing bone lesions. The company is targeting a worldwide market for the treatment of major disorders such as bone and cartilage related arthritis, osteoporosis, and various types of bones and joint trauma such as hip fractures and knee injuries, among others. On April 29, 2012, Bonus Bio Group Ltd fully acquired Bonus Therapeutic Ltd.

BONS Intrinsic Value
0.41 ILS
Overvaluation 96%
Intrinsic Value
Price
B

See Also

Back to Top